Biobanking for bimolecular research

Karine Sargsyan, MD, PhDManaging Director of Biobank

Medical University Graz

Definition

Structured collection of biological material and corresponding data

„hot spots“ for R&D

Tissue

BloodDNA

Biological samples

Data Bank

CellsProteins

OtherBodyfluids

Disease specific data

Personal dataunder Data savity and security

Collection

2Version 3.3

European research infrastructure

Innovative Medicine Initiative (2 Mrd. EUR)

ESFRI – Roadmap (35 Topics)

EATRIS

ELIXIR

INFRAFRONTIER ECRINBBMRI INSTRUCT

Version 3.3

Features of Research Infrastructures

Pan-EuropeanAgreement on long-termstrategyAdded value of cooperationAccessPower of scaleSustainability

Biomedical Research

Bioanalytical Chemistry Technology

Biotechnology

Information Systems/Computer Technology

Imaging Technologies

Animal testing

Drug Substance Manufacture

Survey Technology

Clinical Lab Technology

Clinical trial center

Bioanalytical Chemistry Technology

Clinical trial center

Survey Technology

Clinical Lab Technology

Information Systems/Computer Technology

Animal testing

Access to biological samples

Biobanks in Medical Research

NCI: Biological sampels are #1 roadblockOECD: Global Biological Resource Centre NetworkWHO/IARC: Standards for biological resource centresESF: Science Policy Briefing: Need for integrationEU/ESFRI: Research infrastructure for Biobanks and Biomolecular

Resources (BBMRI)

700,000 Cancer deaths

(North America; 2007)

Cancer Genome Project struggelswith sample shortage(Nature Medicine 2007)

ELSIFragmentation

FundingTechnical

Follow-up

BBMRI

Key Components of BBMRI

Fam. historyLab. param.

Treatm. outcomeLifestyle

PBMC

Serum

FFPEtissues

Frozentissues

Cells

AntibodiesAffinity binders

Recomb. proteins

Gene clone collections*

siRNA libraries*Cell lines*

Model organisms*

Sample storage

Human biological samplesand data

HealthyPopulation

Analysis tools

Patients

ApplicationBasic researchLife sciences

Targets forDrug discovery

Biomarkers forDrug development

New diagnostics

Personalized medicinePublic health

Infrastructure

Data storageBiocomputing

DNA

*: ESFRI BMS report but not funded

Ist-ZustandEuropäisches Umfeld

BBMRI-Partner und assozierte Institutionen

183 Associated organisations28 Countries

50 Participating institutions

Preparatory phase 27 monthsFunding 5 mio €

183 Associated organisations28 Countries

50 Participating institutions183 Associated organisations

28 Countries

50 Participating institutions

Preparatory phase 27 monthsFunding 5 mio €

The New Dimension in Life Sciences Research

networks networks networks

resources, technologiesservices

Individual research groups

pan-European research infrastructures

Access

CollaborationIntegration

Harmonization

CompetitionInnovation

Innovation circle

Benefits for Health Care Systems

Short termStandardization and international harmonization

Quality control and strategic planning

Avoidance of redundancies

Mid termBiological samples and data as a key resource for health care-related economies

Heath care as economic value generator

Long termBetter health care

Personalized medicine

Overview on 7109 Colon Cancer Cases

Overview on 7109 Colon Cancer Cases

Year Sex Age df Survival Staging T Staging N Staging M GradingExamination

96-99) SIGMAMANSCHETTE MIT EINEM OBERFLAECHLICH AUSGEDEHNT EXULCERIERTEN UND BEREITS FORTGESCHRITTEN INVASIVEN, MITTEL-DIFFERENZIERTEN, SAEMTLICHE DARMWANDSCHICHTEN DURCHSETZENDEN UND PERFORIERTEN ADENOKARZINOM MIT EINER KONSIKUTIVEN, ABSZEDIERENDEN UND AUCH PHLEGMONOESEN ENTZUENDUNG IM MITERFASSTEN PARACOLISCHEN FETT-UND BINDEGEWEBE OHNE JEDOCH NACHWEISBAREN LYMPHKNOTENMETASTASEN (RPT-3, PG-2, PN-0, R-0).27 TUMORFREIE HIST. VERIFIZIERBARE PARACOLISCHE

LYMPHKNOTEN SOWIE AUCH TUMORFREIER NETZANTEIL. TUMORFREIE APPENDIX MIT RESIDUEN NACH APPENDICITIS(FOKALE VERNARBUNG DER SUBMUKOSA). FOKALE FIBRINOES GRANULOZYTAERE PERICHOLEZYSTITIS (UEBERGREIFEN DER ENTZUENDUNGSINFILTRATE IM RAHMEN DER VERIFIZIERBAREN SIGMAPERFORATION DURCH DAS TUMORGEWEBE).

Possible Legal Structure of BBMRI (ERIC)

Distributed hub and spoke structure

National members

BiobanksBiomolecular res.Technology centers

Associated partnersHospitalsUniversitiesService providers …

Secretariat(statutory seat)

The Process

Evaluation of existing resources and solutionsIdentification of open issues

Concept for:Integration of existing resourcesIntegration of future resourcesProcess standardization, certificationAccess rulesIncentives and benefit sharingInternational exchange of samples and data

Operational concept Financial Plan Implementation Plan

MoU, Contracts

8 m

o3 m

o10 m

o3 m

o

Starting Points

OECD best practice guidelines for Biological Resource CentresOECD draft guidelines on Human Biobanks and Genetic Research Database

P3GInternational harmonization of biobanking

FP5-FP7, national programsExisting biobanks, resources and networks

The Adaptor Approach of BBMRI

Define criteriaWhich samples and data can becombined?

Develop toolsData exchange

Sample transport

Provide Access

BBMRI Prototype

To accomplish a great vision and complex process in a series of specific steps

Most advanced biobanks should start the construction of a prototype infrastructure already during preparatory phase on a voluntary basis

Requires support from national Funders and Ministries

Expected Impact of BBMRI

BBMRI should provide a pan-European framework to fosterexcellence in biomedical research

Better projects, faster, cheaper

Access to high quality resources, technologies, servicesPartner for academia and industry

SMEs: Strategic partner, customer

Pharma: Biomarker and drug development

Incubator for regional development

Synergies of BMS Research Infrastructures

EATRIS

ELIXIR

INFRAFRONTIER ECRIN

BBMRI

INSTRUCT

TargetId

TargetVal Hit Lead

LeadOptim Preclininc Phase I Phase II

Research Discovery Development

Phase III

e-Infrastructure

EMBRC EISBI EU OpenScreen

Euro Bio-Imaging

BSL4Laboratories

B i o b a n k i n g

B i o i n f o r m a t i c s

PP projects1st update of roadmapEmerging infrastructures

Opportunities for Regional Development

Biological resources are the essential raw material for futurehealt-related economiesBiomarkers are needed to increase the efficacy of drugdevelopment and value generationPart of European Research InfrastructureContact point for and integrator of eastern European resourcesFrom a resource provider to a resource integator and valuegenerator (biomarker center)

Cancer and Thrombosis Study

Hematologic Bank

MyoBANK Wien

AKH Biobank

Serumbank Gynecology

Hematology Biobank

Tissue Bank Gynecology

Prostata Biobank Innsbruck

Biobank der MUG

Vienna Drosophila RNAi CenteICNB

Bleeding Study

Vet Biobank

TissueBody fluids (Blood, sera, etc.) Derivate (DNA, Cell lines, etc.)

Surface is proportional to number of samples

Inventory of BiobanksBBMRI – AT

Inventory of BiobanksBBMRI –Europe

BB MUG

PBCCCM

NCT

TUM

LSH 3

TBGI

Banu BB

HP-CVDRF

NLCS

CRB Bichat

BBI

BMBACS

CNESPS

PBCCBF

ZONCO 3

MORGEN EPICMORGEN

BioPIC

LifeLines

CNIO

CEPH

BNA DN

Biobank 06

KompNet

Tissue, Blood, DNABlood, DNA

Surface is proportional to number of samples

25 Biobanks with the highest number of samples April 2009

Nr. PROJEKTTITELPROJEKTSUMM

E MUG

1 Genetische Marker zur Vorhersage des Verlaufes und Therapieansprechens Dickdarmkarzinomen 53.025,03

2 Bestimmung von c-Kit, PDGFRA, Beta Expression und Genmutation in Desmoid Tumoren 14.000,00

3 Gene-Silencing mittels siRNA in kleinzelligen Lungenkarzinomen 20.000,00

4 Immunhistochemische Marker bei extra-abdominellen aggressiven Fibromatosen 22.454,00

5 Regulation of basophils by chemokine-receptors 3.440,00

6 GOLD3 - Genomics Of Lipid Droplet Biology,Lipid droplet-associated proteins regulating lipid storage 164.414,00

7 GEN-AU III: GATiB 1.087.136,00

8 GENAU I 243.758,00

9 GATiB: Genome Austria Tissue Bank (SP3):Highly annotated tissue sample collection 385.820,10

10 GATiB:Genome Austria Tissue Bank (SP4):Specification documentation metabolic neoplastic iseases 506.730,00

11 GATiB: Genome Austria Tissue Bank (Koordinationsprojekt, SP1) 297.186,52

12 A gene expression data set for breast cancer 94.000,00

13 A comprehensive disease bank for functional genomics. 1.087.136,00

14 SFB LIPOTOX: Teilprojekt des Koordinationsprojekts (Pathophysiologischer Teil) 172.040,00

15 NANO-HEALTH: Nano-TOX 161.639,00

16 VIPEM, Visual Analytics for Personalized Medicine 131.991,00

17 SFB LIPOTOXICITY -Role of hepatobiliary bile acid transporters and nucler receptors in the control 446.880,00

18 Prostaglandin D2 als Mediator der Allergie 240.247,00

19 Geschlechtsspezifische Genexpresssion in Makrophagen 249.795,00

20 Die Rolle von c-Jun und JunB für die Lymphomenstehung 95.161,00

21 Kernrezeptoren als therapeutische Targets bei Cholestase 248.402,00

22 Molekulare Regulation hepatozellulärer Transportsysteme 176.877,00

23 Genexpressionsanalyse der Sarcoidose 173.172,00

24 Neue Mechanismen der selektiven Regulation von Basophilen 166.108,00

25 Pathogenese und Immunologie großzellig-anaplastischer Lymphome 242.080,00

26 SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics 1.032.358,00

27 BBMRI: Biobanking and Biomolecular Resources Research Infrastructure 939.256,00

28 IMPACTS: ARCHIVE´S TISSUES: IMPROVING MOLECULAR MEDICINE RESEARCH AND 655.000,00

29 EPCRC_Biomarker als Nachweis für Schmerzwahrnehung und Therapieansprechen 221.256,00

30 Molecular-cytogenetic and gene expression study of adenocarcinomas possible precursor lesions 2.000,00

31 ESBIC-D European Systems Biology Initiative for combating Complex Diseases 41.200,00

32 PEROXISOMES: Integrated Project to decipher the biological function of peroxisomes 131.731,00

33 PONT: Parallel Optimization of New Technologies for Post-Genomics Drug Discovery 352.200,00

34 Vitamin D and new bone marker levels in breast cancer patients with and without bone metastases 66.000,00

35 Molecular alterations of intestinal bile acid homeostasis in inflammatory bowel disease 49.000,00

36 Type-I Diabetes Mellitus in Early Pregnancy: Effect on Placental Development 81.000,00

37 Rolle der Lipidmediatoren Prostaglandin D2, 5-oxo-ETE in Erkrankungen Respirationstraktes 75.000,00

38 Einfluss einer psychosozialen Intervention auf T und NK Zellfunktion von Patientinnen Mammakarzinom 68.000,00

39 Molekulare Effekte von Ursodeoxycholsäure auf die Expression hepatobiliärer ATP-binding Cassette 94.000,00

40 Plazenta, Fettsäuren und Diabetes 125.000,00

41 European Biobanking and Biomolecular Resources Infrastructure 30.390,00

42 Pathogenese endometrialen Stromasarkoms -SALDOW 1.764.574,00

43 Healthcare integrated Biobanking (RP7 Health 1. Stufe) 20.000,00

44 IMI European Medicines Research Training Network_NEBRIC 16.700,00

45 ARCSCREEN 5.275,00

46 High throughput biobanking technologies for tissues, cells and body fluids 12.000,00

47 Schwangerschaftsdiabetes 11.900,00

48 Vertragsverhandlungen zum EU-Projekt BBMRI 7.500,00

49 GENOPTIKUM 182.240,00

50 RZPD - CRIP 396.585,00

51 GENINCA 12.300,00

52 Evaluation of prognostic factors in patients with spinal metastases 3.000,00

53 GEN-View 153.100,00

54 Nano-HEALTH Verlengerung 530.000,00

55 Molekulargenetische Analysen von Knochen- und Weichteiltumoren 30.000,00

Gesamt 13.592.056,65

Version 3.3

Ausschließlich akademische Projekte im Biobank-Umfeld, ohne Industrie und klinische Studien

Projekte, die ohne Biobank nicht entstanden wären

Projects

24

Projects ( since 2005)

nur Anteil MUG, Gesamtprojektvolumen um vieles höher

Biobank

Projekt level

Infrastructur

General structure

25Version 3.3

Projekt-Ebene

Infrastruktur-Ebene

26

BIOBANKResearch

infrastructur

Academic and industrialCooperative research

Academicresearch

Industrialresearch

General structure

Version 3.3

Biobank

27Version 3.3

Planed SEE Projects

Harmonization of Clincal BiobanksSEEBI (South East European Biobanking Initiative)

Biobank-InfrastructureTEMPUS

WHO/ IACR - Trainingsprogramm

Proposed BBMRI Assets and Services

Handbook for operation of biobanksOpen source IT-solutionsStatistical powerhouseAdvice for QC and certificationGuidance to European ELSI landscapeTemplates for IC, MTA, CDAISO-certified analysis platformsBiomolecular resourcesTraining and educationModel for regional development

Mid-term Strategy

Biobank and biospecimen research is a specificstrength of MUGFrom a local resource provider to a global integratorBiobank research infrastructure as nucleus for ECIScientific focus on translational research

From models to humansFrom basic science to application

Biobank der MUGhttp://www.meduni-graz.at/1449biobank@meduni-graz.atTel: +43 316 385 72716Fax: +43 316 385 73009

Thanks for your attention